Histogen Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-11-01: Form 8-K; Period of report 2017-11-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-09-01: Form 8-K; Period of report 2017-08-31; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2017-08-02: Form 8-K; Period of report 2017-08-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-07-06: Form 8-K; Period of report 2017-07-05; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-11-01 | 8-K | 2017-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2017, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and nine months ended September 30, 2017. | f8k_110117.htm |
| 2017-09-01 | 8-K | 2017-08-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective August 31, 2017, the board of directors of Conatus Pharmaceuticals Inc. (the “Company”) appointed Keith W. Marshall, Ph.D., M.B.A., as the Company’s Executive Vice President, Chief Operating Officer and Chief Financial Officer. | f8k_090117.htm |
| 2017-08-02 | 8-K | 2017-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2017, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and six months ended June 30, 2017. | f8k_080217.htm |
| 2017-07-06 | 8-K | 2017-07-05 | 8.01 Other Events | 8.01 On July 5, 2017, the exclusive license granted by Conatus Pharmaceuticals Inc. (“Conatus”) to Novartis Pharma AG (“Novartis”) for the global development and commercialization of emricasan became effective under terms of the Option, Collaboration and License Agreement dated December 19, 2016 (the “Collaboration Agreement”). | f8k_070617.htm |
| 2017-06-26 | 8-K | 2017-06-22 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Conatus Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders on June 22, 2017. | f8k_062617.htm |
| 2017-05-11 | 8-K | 2017-05-10 | 8.01 Other Events | 8.01 On May 11, 2017, Conatus Pharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated and SunTrust Robinson Humphrey, Inc., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 5,200,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). | d212383d8k.htm |
| 2017-05-04 | 8-K | 2017-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2017, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended March 31, 2017. | f8k_050417.htm |
| 2017-05-04 | 8-K | 2017-05-03 | 8.01 Other Events | 8.01 On May 3, 2017, Conatus Pharmaceuticals Inc. (“Conatus”) announced that Novartis Pharma AG (“Novartis”) has exercised its option to an exclusive license for the global development and commercialization of emricasan, Conatus’ first-in-class, orally-active pan-caspase inhibitor, under terms of an Option, Collaboration and License Agreement (the “Collaboration Agreement”) entered into with Novartis in December 2016. | f8k_050417.htm |
| 2017-03-21 | 8-K | 2017-03-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 16, 2017, the board of directors of Conatus Pharmaceuticals Inc. (the “Company”) appointed Steven J. Mento, Ph.D. as the Company’s acting Principal Financial Officer and appointed Michelle L. Vandertie as the Company’s acting Principal Accounting Officer, each to be effective on March 31, 2017 upon the effectiveness of the previously announced resignation of Charles J. Cashion, the Company’s Senior Vice President, Finance, Chief Financial Officer and Secretary. | f8k_032117.htm |
| 2017-03-15 | 8-K | 2017-03-15 | 2.02 Results of Operations and Financial Condition | 2.02 On March 15, 2017, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2016. | f8k_031517.htm |
| 2017-02-17 | 8-K | 2017-02-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 16, 2017, Charles J. Cashion tendered his resignation as Senior Vice President, Finance, Chief Financial Officer and Secretary of Conatus Pharmaceuticals Inc. (the “Company”), a position which he has held since co-founding the Company in 2005. | f8k_021717.htm |
| 2017-02-16 | 8-K | 2017-02-15 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On February 15, 2017, Conatus Pharmaceuticals Inc. (the “Company”) issued a convertible promissory note in the principal amount of $15 million (the “Note”) to Novartis Pharma AG (“Novartis”). 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | f8k_021617.htm |
| 2017-02-07 | 8-K | 2017-02-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of February 6, 2017, upon the recommendation of the nominating and corporate governance committee, and pursuant to the bylaws of Conatus Pharmaceuticals Inc. (the “Company”), the Board of Directors (the “Board”) of the Company appointed William R. LaRue to the Board. | f8k_020717.htm |
| 2017-02-01 | 8-K | 2017-01-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 26, 2017, the Compensation Committee of the Board of Directors of Conatus Pharmaceuticals Inc. established the base salaries to be paid to the executive officers listed below, effective January 1, 2017, set target cash bonuses for the 2017 fiscal year for each of the executive officers listed below and approved cash bonus payments for the 2016 fiscal year to be paid to each of the executive officers listed below. | f8k_020117.htm |
| 2017-01-26 | 8-K | 2017-01-24 | 1.02 Termination of a Material Definitive Agreement | 1.02 On January 24, 2017, Conatus Pharmaceuticals Inc. (the “Company”) voluntarily prepaid the Promissory Note, dated July 29, 2010, as amended on July 3, 2013, by and between the Company and Pfizer Inc. (the “Promissory Note”). | f8k_012617.htm |